Table 3.
Main clinical characteristics of JIA population in relation to VDR polymorphisms.
| Number of patients | ApaI | BsmI | Cdx2 | FokI | TaqI | |
|---|---|---|---|---|---|---|
| JIA subtype | ||||||
| Oligoarticular JIA | 46 | TT 27 (58.7%) | GG 11 (23.9%) | GG 26 (56.5%) | CC 22 (47.8%) | TT 11 (23.9%) |
| TG 17 (37.0%) | GA 28 (60.9%) | GA 17 (37.0%) | CT 17 (37.0%) | TC 25 (54.3%) | ||
| GG 2 (4.3%) | AA 7 (15.2%) | AA 3 (6.5%) | TT 7 (15.2%) | CC 10 (21.8%) | ||
| Extended oligoarticular JIA | 8 | TT 2 (25.0%) | GG 3 (37.5%) | GG 5 (62.5%) | CC 5 (62.5%) | TT 2 (25.0%) |
| TG 5 (62.5%) | GA 4 (50.0%) | GA 3 (37.5%) | CT 2 (25.0%) | TC 4 (50.0%) | ||
| GG 1 (12.5%) | AA 1 (12.5%) | AA 0 (0%) | TT 1 (12.5%) | CC 2 (25.0%) | ||
| Polyarticular JIA | 33 | TT 16 (48.5%) | GG 9 (27.2%) | GG 19 (57.6%) | CC 16 (48.5%) | TT 16 (48.5%) |
| TG 10 (30.3%) | GA 19 (57.6%) | GA 13 (39.4%) | CT 15 (45.4%) | TC 11 (33.3%) | ||
| GG 7 (21.2%) | AA 5 (15.2%) | AA 1 (3.0%) | TT 2 (6.1%) | CC 6 (18.2%) | ||
| Psoriatic arthritis | 7 (4 of them oligo, 1 poly and 2 not indicated) | TT 4 (57.1%) | GG 5 (71.4%) | GG 4 (57.1%) | CC 1 (14.3%) | TT 2 (28.6%) |
| TG 1 (14.3%) | GA 1 (14.3%) | GA 2 (28.6%) | CT 4 (57.1%) | TC 2 (28.6%) | ||
| GG 2 (28.6%) | AA 1 (14.3%) | AA 1 (14.3%) | TT 2 (28.6%) | CC 3 (42.8%) | ||
| Enthesitis-related arthritis (ERA) | 6 | TT 3 (50.0%) | GG 2 (33.3%) | GG 4 (66.7%) | CC 2 (33.3%) | TT 2 (33.3%) |
| TG 2 (33.3%) | GA 2 (33.3%) | GA 2 (33.3%) | CT 3 (50%) | TC 2 (33.3%) | ||
| GG 1 (16.7%) | AA 2 (33.3%) | AA 0 (0%) | TT 1 (16.7%) | CC 2 (33.3%) | ||
| Patients for whom the specific JIA subtype has not been reported in the clinical database | 3 | TT 1 (33.3%) | GG 1 (33.3%) | GG 2 (66.7%) | CC 0 (0%) | TT 2 (66.7%) |
| TG 2 (66.7%) | GA 2 (66.7%) | GA 0 (0%) | CT 3 (100%) | TC 1 (33.3%) | ||
| GG 0 (0%) | AA 0 (0%) | AA 1 (33.3%) | TT 0 (0%) | CC 0 (0%) | ||
| JIA clinical presentation | ||||||
| Non-active disease | 57 | TT 29 (50.9%) | GG 15 (26.3%) | GG 33 (57.9%) | CC 27 (47.4%) | TT 20 (35.1%) |
| TG 20 (35.1%) | GA 35 (61.4%) | GA 22 (38.6%) | CT 25 (43.8%) | TC 27 (47.4%) | ||
| GG 8 (14.0%) | AA 7 (12.3%) | AA 2 (3.5%) | TT 5 (8.8%) | CC 10 (17.5%) | ||
| Active disease | 46 | TT 24 (52.1%) | GG 16 (34.8%) | GG 27 (58.7%) | CC 19 (41.3%) | TT 15 (32.6%) |
| TG 17 (37%) | GA 21 (45.7%) | GA 15 (32.6%) | CT 19 (41.3%) | TC 18 (39.1%) | ||
| GG 5 (10.9%) | AA 9 (19.5%) | AA 4 (8.7%) | TT 8 (17.4%) | CC 13 (28.3%) | ||
| Serum 25(OH) vitamin D | ||||||
| Vitamin D deficiency | 4 | TT 2 (50%) | GG 2 (50%) | GG 2 (50%) | CC 1 (25%) | TT 1 (25%) |
| TG 1 (25%) | GA 1 (25%) | GA 2 (50%) | CT 3 (75%) | TC 1 (25%) | ||
| GG 1 (25%) | AA 1 (25%) | AA 0 (0%) | TT 0 (0%) | CC 2 (50%) | ||
| Vitamin D insufficiency | 83 | TT 44 (53.0%) | GG 24 (28.9%) | GG 50 (60.3%) | CC 37 (44.6%) | TT 30 (36.1%) |
| TG 25 (30.1%) | GA 45 (54.2%) | GA 27 (32.5%) | CT 36 (43.4%) | TC 35 (42.2%) | ||
| GG 14 (16.9%) | AA 14 (16.9%) | AA 6 (7.2%) | TT 10 (12.0%) | CC 18 (21.7%) | ||
| Vitamin D sufficiency | 15 | TT 6 (40.0%) | GG 4 (26.7%) | TT 3 (20.0%) | GG 7 (46.7%) | CC 7 (46.7%) |
| TG 9 (60.0%) | GA 10 (66.7%) | TC 9 (60.0%) | GA 8 (53.3%) | CT 5 (33.3%) | ||
| GG 0 (0%) | AA 1 (6.6%) | CC 3 (20.0%) | AA 0 (0%) | TT 3 (20.0%) | ||
| Vitamin D high level (> 100 ng/ml) | 1 | TT 0 (0%) | GG 1 (100%) | TT 0 (0%) | GG 1 (100%) | CC 1 (100%) |
| TG 1 (100%) | GA 0 (0%) | TC 1 (100%) | GA 0 (0%) | CT 0 (0%) | ||
| GG 0 (0%) | AA 0 (0%) | CC 0 (0%) | AA 0 (0%) | TT 3 (0%) | ||
| Bone status | ||||||
| Osteopenia | 29 | TT 16 (55.2%) | GG 9 (31.0%) | GG 20 (69.0%) | CC 13 (44.9%) | TT 13 (44.9%) |
| TG 7 (24.1%) | GA 16 (55.2%) | GA 8 (27.6%) | CT 11 (37.9%) | TC 11 (37.9%) | ||
| GG 6 (20.7%) | AA 4 (13.8%) | AA 1 (3.4%) | TT 5 (17.2%) | CC 5 (17.2%) | ||
| Normal BMD value | 73 | TT 36 (49.3%) | GG 22 (30.1%) | GG 40 (54.8%) | CC 32 (43.8%) | TT 22 (30.1%) |
| TG 30 (41.1%) | GA 39 (53.4%) | GA 28 (38.4%) | CT 33 (45.2%) | TC 33 (45.2%) | ||
| GG 7 (9.6%) | AA 12 (16.4%) | AA 5 (6.8%) | TT 8 (11.0%) | CC 18 (24.7%) | ||
| PTH serum level | ||||||
| Low PTH serum level | 6 | TT 1 (16.7%) | GG 2 (33.3%) | TT 2 (33.3%) | GG 3 (50.0%) | CC 2 (33.3%) |
| TG 5 (83.3%) | GA 3 (50.0%) | TC 4 (66.7%) | GA 3 (50.0%) | CT 4 (66.7%) | ||
| GG 0 (0%) | AA 1 (16.7%) | CC 0 (0%) | AA 0 (0%) | TT 0 (0%) | ||
| Normal PTH value | 97 | TT 52 (53.6%) | GG 29 (29.9%) | TT 33 (34.0%) | GG 57 (58.8%) | CC 44 (44.4%) |
| TG 32 (33.0%) | GA 53 (54.6%) | TC 41 (42.3%) | GA 34 (35.0%) | CT 40 (41.2%) | ||
| GG 13 (13.4%) | AA 15 (15.5%) | CC 23 (23.7%) | AA 6 (6.2%) | TT 13 (13.4%) | ||